Abstract

Functional heterologous expression of naturally expressed mouse α6*-nicotinic acetylcholine receptors (mα6*-nAChRs; where "*" indicates the presence of additional subunits) has been difficult. Here we expressed and characterized wild-type (WT), gain-of-function, chimeric, or gain-of-function chimeric nAChR subunits, sometimes as hybrid nAChRs containing both human (h) and mouse (m) subunits, in Xenopus oocytes. Hybrid mα6mβ4hβ3- (∼ 5-8-fold) or WT mα6mβ4mβ3-nAChRs (∼ 2-fold) yielded higher function than mα6mβ4-nAChRs. Function was not detected when mα6 and mβ2 subunits were expressed together or in the additional presence of hβ3 or mβ3 subunits. However, function emerged upon expression of mα6mβ2mβ3(V9'S)-nAChRs containing β3 subunits having gain-of-function V9'S (valine to serine at the 9'-position) mutations in transmembrane domain II and was further elevated 9-fold when hβ3(V9'S) subunits were substituted for mβ3(V9'S) subunits. Studies involving WT or gain-of-function chimeric mouse/human β3 subunits narrowed the search for domains that influence functional expression of mα6*-nAChRs. Using hβ3 subunits as templates for site-directed mutagenesis studies, substitution with mβ3 subunit residues in extracellular N-terminal domain loops "C" (Glu(221) and Phe(223)), "E" (Ser(144) and Ser(148)), and "β2-β3" (Gln(94) and Glu(101)) increased function of mα6mβ2*- (∼ 2-3-fold) or mα6mβ4* (∼ 2-4-fold)-nAChRs. EC50 values for nicotine acting at mα6mβ4*-nAChR were unaffected by β3 subunit residue substitutions in loop C or E. Thus, amino acid residues located in primary (loop C) or complementary (loops β2-β3 and E) interfaces of β3 subunits are some of the molecular impediments for functional expression of mα6mβ2β3- or mα6mβ4β3-nAChRs.

Highlights

  • Expressed mouse (m) ␣6*-Nicotinic acetylcholine receptors (nAChRs) have negligible functional expression in vitro

  • (15) we have shown that coexpression of WT nAChR ␣6 and ␤2 subunits alone or in combination with ␤3 or ␤3V9ЈS subunits in oocytes, all from a single species, did not yield consistent and reproducible current responses to nicotinic agonists

  • We injected about ϳ3.5 ng of Complementary RNA (cRNA) for each nAChR subunit to express hybrid nAChRs, but later we increased amounts injected to ϳ23 ng for each subunit to emulate the approach taken by Kuryatov et al (14) to express functional human ␣6␤4*-nAChRs

Read more

Summary

Background

Expressed mouse (m) ␣6*-nAChRs have negligible functional expression in vitro. Functional heterologous expression of naturally expressed mouse ␣6*-nicotinic acetylcholine receptors (m␣6*-nAChRs; where “*” indicates the presence of additional subunits) has been difficult. We expressed and characterized wild-type (WT), gain-of-function, chimeric, or gain-of-function chimeric nAChR subunits, sometimes as hybrid nAChRs containing both human (h) and mouse (m) subunits, in Xenopus oocytes. We recently succeeded in producing functional, hybrid ␣6␤3*-nAChRs substituting mouse (m) ␣6 subunits for human (h) ␣6 subunits to express functional m␣6h␤4h␤3- or m␣6h␤2h␤3V9ЈS-nAChRs (15) This kind of study leveraging innate variations in amino acid (AA) residues between subunits from different species produced valuable information regarding structure and function of invertebrate and vertebrate nAChRs (15, 21, 33, 34). These studies elucidate some of the structural bases dictating roles for nAChR ␤3 subunits in functional expression of m␣6m␤2*- and m␣6m␤4*-nAChRs

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call